Sign In
Buy CGEN
$2.34
-0.0700 (-2.90%)
At Close: Aug 10, 2026
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
09:26am, Tuesday, 06'th Aug 2024
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
Compugen Reports Second Quarter 2024 Results
07:00am, Tuesday, 06'th Aug 2024
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer stud
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
07:00am, Monday, 29'th Jul 2024
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer t
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
07:00am, Tuesday, 23'rd Jul 2024
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen to Present at Upcoming Antibody Industrial Symposium
07:00am, Monday, 17'th Jun 2024
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announce
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Tuesday, 04'th Jun 2024
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
07:00am, Thursday, 30'th May 2024
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th
Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
12:22pm, Monday, 20'th May 2024
Compugen Ltd. (NASDAQ:CGEN ) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Monday, 20'th May 2024
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago.
Compugen Reports First Quarter 2024 Results
07:00am, Monday, 20'th May 2024
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsate
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
07:00am, Thursday, 16'th May 2024
HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th
Compugen Appoints David Silberman as Chief Financial Officer
07:00am, Wednesday, 15'th May 2024
HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
07:00am, Monday, 06'th May 2024
HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t
HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announce
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
07:00am, Wednesday, 10'th Apr 2024
HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announce
